What is new in degenerative dementia disorders?

Wiener Klinische Wochenschrift

Volumn 111, Issue 17, 1999, Pages 682-704

  Jellinger, Kurt A ^a,b  

^a Gen Intensive Care (B) W   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Alzheimer disease; Dementia; Diagnostic criteria; Frontotemporal dementia; Lewy body dementia; Management; Molecular genetics; Morphology

Indexed keywords

2,8 DIMETHYL 3 METHYLENE 1 OXA 8 AZASPIRO[4.5]DECANE; 3 (2 DIETHYLAMINO 2 METHYLPROPYLAMINO) 6 PHENYL 5 PROPYLPYRIDAZINE; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; 8 [3 (4 DIETHYLCARBAMOYL 1 PIPERAZINYL)PROPYL] 1,3,7 TRIMETHYLXANTHINE; CEVIMELINE; DONEPEZIL; GALANTAMINE; METRIFONATE; PHYSOSTIGMINE; RIVASTIGMINE; SABCOMELINE; SYNAPTON; TACRINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; DEMENTIA; EARLY DIAGNOSIS; FRONTOTEMPORAL DEMENTIA; HUMAN; LEWY BODY; MOLECULAR GENETICS; QUALITY OF LIFE; REVIEW; SOCIOECONOMICS;

ALZHEIMER DISEASE; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEWY BODY DISEASE; RISK FACTORS;

EID: 0033578976     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (252)

1. Aguero-Torres H, Fratiglioni L, Guo ZC, Viitanen M, Vonstrauss E, Winblad B (1998) Dementia is the major cause of functional dependence in the elderly - 3-year follow-up data from a population-based study. Am J Public Health 88: 1452-1456
2. Akserov MY, Tucker HM, Nair P, Aksenovs MV, Butterfield DA, Estus S, et al (1998) The expression of key oxidative stress-handling genes in different brain regions in Alzheimer's disease. J Molec Neurosci 11: 151-164
3. Albert SM, Costa R, Merchant C, Small S, Jenders RA, Stern Y (1999) Hospitalitization and Alzheimer's disease. Results from a community-based study. J Gerontol A Biol Sci Med Sci 54: M267-M271
4. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer Disease (1995) Statement on use of apolipoprotein E testing for Alzheimer disease. JAMA 274: 1627-1629
5. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DC
6. Andersen K, Nielsen H, Lolk A, Andersen J, Becker I, Kragh-Sørensen P (1999) Incidence of very mild to severe dementia and Alzheimer's disease in Denmark: The Odense Study. Neurology 52: 85-90
7. Andreasen N, Hesse C, Davidson P, et al (1999) Cerebrospinal fluid β-amyloid (1-42) in Alzheimer disease. Differences between early and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 56: 673-680
8. Arendt T, Holzer M, Gertz HJ, Brückner MK (1999) Cortical load of PHF-tau in Alzheimer's disease is correlated to cholinergic dysfunction. J Neural Transm 106: 513-523
9. Axelman K, Basun H, Lannfelt L (1998) Apolipoprotein E and α(1)-antichymotrypsin genotypes and age of onset of familial Alzheimer's disease. Dement Geriat Cogn Disord 10: 1-5
10. Baba M, Nakajo S, Tu P-H, Tomita T Nakaya K, Lee VM-Y, et al (1998) Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 152: 879-884
11. Ballard C, Holmes C, McKeith I, et al (1999) Psychiatric morbidy in dementia with Lewy bodies. A prospective clinical and neuropathological comparative study with Alzheimer's disease. Am J Psychiatry 156: 1039-1045
12. Baker M, Litvan I, Houlden H, Adamson J, Dickson D. et al (1999) Association of and extended haplotype in the tau gene with progressive supranuclear palsy. Hum Molec Genet 8: 711-715
13. Baldereschi M, DiCarlo A, Maggi S, Grigoletto F, Scarlato G, et al (1999) Dementia is a major predictor of death among the Italian elderly. Neurology 52: 709-713
14. Bancher C, Croy A, Dal Bianco P, Danielczyk W, Fischer P, Gatterer G, et al (1998) Österreichisches Alzheimer-Krankheit-Konsensuspapier. Neuropsychiatrie 12: 126-167
15. Baran H, Jellinger K, Deecke L (1999) Kynurenin metabolism in Alzheimer's disease. J Neural Transm 106:165-181
16. Barber R, Gholkar A, Scheltens P, Ballard C, McKeith LG, O'Brien JT (1999) Medial temporal lobe atrophy on MRI in dementia with Lewy bodies. Neurology 52: 1153-1158
17. Bass MP, Yamaoka LH, Scott WK, Gaskell PC, Welshbohmer KA, Roses AD, et al (1998) No association of α-1-antichymotrypsin flanking region polymorphism and Alzheimer's disease risk in early-and late-onset Alzheimer's disease patients. Neurosci Lett 250: 79-82
18. Beach TG, Honer WG, Hughes LH (1997) Cholinergic fibre loss associated with diffuse plaques in the non-demented elderly: the preclinical stage of Alzheimer's disease? Acta Neuropathol 93: 146-151
19. Beal MF (1998) Bioenergetics, excitatory, and oxidative injury in the pathogenesis of neurodegenerative disease. In: Growdon HJ, Rossor MN (eds) The dementias. Butterworth Heineman, Boston, pp 305-331
20. Behl C (1999) Alzheimer's disease and oxidative stress; implications for novel therapeutic approaches. Prog Neurobiol 57: 301-323
21. Bennett P, Bonifati V, Bonuccelli U, Colosimo C, Demari M, et al (1998) Direct genetic evidence for involvemant of tau in progressive supranuclear palsy. Neurology 51: 982-985
22. Berg L, McNeel DW, Miller P, Storandt M, Rubin EH, et al (1998) Clinicopatholgic studies in cognitively healthy aging and Alzheimer's disease. Arch Neurol 5S: 326-335
23. Bergeron C, Davis A, Lang AE (1998) Corticobasal ganglionic degeneration and progressive supranuclear palsy presenting with cognitive decline. Brain Pathol 8: 355-365
24. Binett G, Growdon JH, Vonsattel JPG (1998) Pick's disease. In: Growdon HJ, Rossor MN (eds) The dementias. Butterworth Heinemann, Boston, pp 7-44
25. Bird TD, Nochlin D, Poorkaj P, et al (1999) A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P302L). Brain 122:741-756
26. Blacker D, Tanzi RE (1998) The genetics of Alzheimer's disease - current status and future prospects (Review). Arch Neurol 55: 294-296
27. Blacker D, Wilcox MA, Laird NM, Rodes L, et al (1998) α-2-macroglobulin is genetically associated with Alzheimer disease. Nature Genet 19: 357-359
28. Bowhler JV, Munoz DG, Merskey H, Hachinski V (1998) Fallacies in the pathological confirmation of the diagnosis of Alzheimer's disease. J Neurol Neurosurg Psychiatry 64: 18-24
29. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239-259
30. Breitner JCS, Wyse BK, Antony JC et al (1999) APOE-ε4 count predicts age when prevalence of AD increases. then declines. The Coche County study. Neurology 53: 321-331
31. Briel RCG, NcKeith TG, Barker WA, Hewitt Y, Perry RH, Ince PG, Fairbairn AF (1999) EEC findings in dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry 66: 401-403
32. Brindle N, Song Y, Rogaeva E, Premkumar S, Levesque G, Yu G, et al (1998) Analysis of the butyrylcholinesterase gene and nearby chromosome 3 markers in Alzheimer disease. Hum Mol Gen 7: 933-935
33. Brown DF, Dababo MA, Bigio EH, et al. (1998) Neuropathologic evidence that the Lewy body variant of Alzheimer's disease represents coexistance of Alzheimer's disease and idiopathic Parkinson's disease. J Neuropathol Exp Neurol 57: 39-46
34. Brown DF, Risser RC, Bigio EH, Tripp P, Stiegler A, Welch E, et al (1998) Neocortical synapse density and Braak stage in the Lewy body variant of Alzheimer disease - a comparison with classic Alzheimer disease and normal aging. J Neuropathol Exp Neurol 57: 955-960
35. Brun A, Englund E, Gustafson L, Passant U, Mann DMA, Neary D, et al (1994) Clinical and neuropathological criteria for fronto-temporal dementia. J Neurol Neurosurg Psychiatry 57: 416-418
36. Callahan LM, Vaules WA, Coleman PD (1999) Quantitative decrease in synaptophysin message expression and increase in cathepsin D message expression in Alzheimer disease neurons containing neurofibrillary tangles. J Neuropathol Exp Neurol 58: 275-287
37. Cervilla JA, Russ C. Holmes C, Aitchison K, Smith CAD, Powell J, et al (1999) CYP2D6 polymorphisms in Alzheimer's disease, with and without extrapyramidal signs, showing no apolipoprotein E ε-4 effect modification. Biol Psychiatry 45: 426-429
38. Chow IW, Miller BL, Hayashi VN, Geschwind DH (1999) Inheritance of frontotemporal dementia. Arch Neurol 56: 817-822
39. Churchyard A, Lees AJ (1997) The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. Neurology 49: 1570-1578
40. Claus JJ, Strijers RL, Jonkman FJ et al (1999) The diagnostic value of elkectroencephalography in mild senile Alzheimer's disease. Clin Neurophysiol 119: 825-832
41. Connor DJ, Salmon DP, Sandy TJ, Galasko D, Hansen LA, Thal LJ (1998) Cognitive profiles of autopsy-confirmed Lewy body variant vs pure Alzheimer-disease. Arch Neurol 55: 994-1000
42. Corder EH, Lannfelt L, Bogdanovic N, Fratiglioni L, Mori H (1998) The role of apoe polymorphisms in late-onset dementias (Review). Cell Molec Life Sci 54: 928-934
43. Corey-Bloom J, Thai LJ, Galasko D, Folstein M, Drachman D, Raskind M, et al (1995) Diagnosis and evaluation of dementia. Neurology 45: 211-218
44. Cotman CW, Cribas DH, Pike CJ, Ivins HJ (1998) Cell death in Alzheimer's disease. In: Locksmik RA, Zakeri Z. Tilly JL (eds) When cells die. Wiley-Liss, New York, pp 385-409
45. Cruts M, Van Broeckhoven C (1998) Molecular genetics of Alzheimer's disease. In: Growdon HJ, Rossor MN (eds) The dementias. Butterworth Heineman, Boston, pp 155-185
46. Cruts M, Vanduijn CM, Backhovens H, Vandenbroeck M, Wehnert A, Serneels S et al (1998) Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population based study of presenile Alzheimer's disease. Hum Molec Genet 7: 43-51
47. Cummings BH, Cotman CW (1995) Image analysis of β-amyloid load in Alzheimer's disease and relation to dementia severity. Lancet 346: 1524-1528
48. Cummings JL, Benson DP (1992) Dementia. A clinical approach, 2nd edn. Butterworth Heinemann, Boston
49. Cummings JL, Vinters HV, Cole MG, Khachaturian ZS (1998) Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 51: S2-SI7
50. Davis DG, Schmitt FA, Wekstein DR, Markesberry WR (1999) Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 58: 376-388
51. Delacourte A, David J, Sergeant N, Buée L, Wattez A, Vermersch P, et al (1999) The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 52: 1158-1165
52. Delacourte A, Sergeant N, Wattez A, Gauvreau D, Robitaille Y (1998) Vulnerable neuronal subsets in Alzheimer's and Pick's disease are distinguished by their tau isoform distribution and phosphorylation. Ann Neurol 43: 193-204
53. Delisle M-B, Murrell JR, Richardson R, et al (1999) A A mutation at codon 279 (N279K) in exon 10 of the tau gene causes a tauopathy with dementia and supranuclear palsy. Acta Neuropathol 98: 62-77
54. Dickson DW (1998) Pick's disease: a modern approach. Brain Pathol 8: 339-354
55. Di Luca M, Putroino L, Biachini A, Perez J, Vignola LA, et al (1998) Differential level of platelet aryloid b precursor protein isoforms. An early marker for Alzheimer's disease. Arch Neurol 55: 1195-2000
56. Dinkel R (1996) Die Entwicklung der Demenz in der Bundesrepublik Deutschland bis zum Jahr 2050. Gesundheitswesen 58: 50-55
57. Duncan BA, Siegal AP (1998) Early diagnosis and management of Alzheimer's disease. J Clin Psychiatry 59 [Suppl 9]: 15-21
58. D'Souza I, Poorkaj P, Hong M, et al (1999) Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type by affecting multiple alternative RNA splicing regulatory elements. Proc Null Acad Sci USA 96: 5595-5603
59. European Concerted Action on Pick's Disease (ECAPD) Consortium (1998) Provisional clinical and neuroradiological criteria for the diagnosis of Pick's disease. Eur J Neurol 5: 519-520
60. Ewbank DC (1999) Deaths attributable to Alzheimer's disease in the United States. Am J Public Health 89: 90-92
61. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA 278: 1349-1355
62. Fleming KC, Adams AC, Petersen RC (1995) Dementia: diagnosis and evaluation. Mayo Clin Proc 70: 1093-1107
63. Foster NL, Wilhelmsen K, Sima AAF, Jones MZ, D'Amato CJ, Gilman S, et al (1997) Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Ann Neurol 41: 706-715
64. Francis PT, Palmer AM, Snape M, Wilcock GW (1999) The cholinergic hypothesis of Alzheimer's disease; a review of progress. J Neurol Neurosurg Psychiatry 66: 137-147
65. Frisoni GB, Laakso MP, Betramello A, Geroldi C, Bianchetti A, Soininen H, Trabucchi M (1999) Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and Alzheimer's disease. Neurology 52: 91-100
66. Galanta E, Muggia S, Spinnler H, Zuffi (1999) Degenerative dementia of the frontal type. Dement Geriatr Cogn Disord 10: 28-39
67. Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, et al (1998) High cerebrospinal fluid tau and low amyloid β-42 levels in the clinical diagnosis of Alzheimer-disease and relation to apolipoprotein E genotype. Arch Neurol 55: 937-945
68. Galasko D, Hansen LA, Katzman R, Wiederholt W, Masliah E, Terry RD, et al (1994) Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 51: 888-895
69. Gambassi G, Landi F, Lapane KL, et al (1999) Predictors of morrtality in patients with Alzheimer's disease being in nursing homes. J Neurol Neurosurg Psychiatry 67: 59-65
70. Gambetti P (1997) Prion in progressive subcortical glioses revisited. Neurology 49: 309-310
71. Gao S, Hendrie HC, Hall KS, Hui S (1998) The relationship between age, sex and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch Gen Psychiatr 55: 809-815
72. Gauthier S (ed) (1999) Clinical diagnosis and management of Alzheimer's disease, 2nd edn. Martin Dunitz Ltd., London
73. Gearing M, Lynn M, Mirra SS 1999) Neurofibrillary pathology in Alzheimer's disease with Lewy bodies -Two subgroups. Arch Neurol 56: 203-208
74. Gearing M, Schneider JA, Rebeck GW, et al. (1995) Alzheimer's disease with and without coexisting Parkinson's disease changes: apolipoprotein E genotype and neuropathologic correlates. Neurology 45: 1985-1990
75. Geddes JF, Vowles GH, Nicoll JAR, Revesz T (1999) Neuronal cytoskeletal changes are an early consequence of repetive head injury. Acta Neuropathol 98: 171-178
76. Geldmacher DS, Whitehouse PJ (1996) Evaluation of dementia. N Engl J Med 335: 330-336
77. Gertz HJ, Xuereb J, Huppert F, Brayne C, McGee MA, Paykel E, et al (1998) Examination of the validity of the hierarchical model of neuropathological staging in normal aging and Alzheimer's disease. Acta Neuropathol 95: 154-158
78. Geschwind D, Karriim J, Nelson SF, Miller B (1998) The apolipoprotein E ε4 allele is not a significant risk factor for frontotemporal dementia. Ann Neurol 44: 134-138
79. Geula C, Mesulam MM, Saroff DM, Wu C-K (1998) Relationship between plaques, tangles, and loss of cortical cholinergic fibers in Alzheimer's disease. J Neuropathol Exp Neurol 57: 63-75
80. Ghebremedhin E, Schulz C, Braak E, Braak H (1998) High frequency of apolipoprotein E ε4 allele in young individuals with very mild Alzheimer's disease-related neurofibrillary changes. Exp Neurol 153: 152-155
81. Goate AM (1998) Monogenetic determinants of Alzheimer's disease - APP mutations (Review). Cell Molec Life Sci 54: 897-901
82. Goedert M, Jakes R, Spillantini MG (1998) Alpha-synuclein and the Lewy body. Neurosci News 1: 47-52
83. Goedert M, Spillantini MG, Crowther RA, Chen SG, Parchi P, Tabaton M, et al (1999) Tau gene mutation in familial progressive subcortical gliosis. Nature Med 5: 454-457
84. Gomez-Isla T, Hollister R, West H, et al (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 41: 17-24
85. Gomez-Isla T, West HL, Rebeck GW, et al (1996) Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease. Ann Neurol 39: 62-70
86. Growdon JH (1998) Apolipoprotein E and Alzheimer's disease. Arch Neurol 55: 1053-1054
87. Growdon JH, Rossor MN (eds) (1998) The dementias. Butterworth Heinemann, Boston
88. Grundman Q, Coery-Bloom J, Thai LJ (1998) Perspectives in clinical Alzheimer's disease research and the development of antidementia drugs. J Neural Transm [Suppl 53]: 255-275
89. Gsell W, Strein I, Riederer P (1996) The neurochemistry of Alzheimer type, vascular type and mixed type dementias compared. J Neural Transm [Suppl 47]: 73-101
90. Guo Q, Fu W, Sopher BL, Miller MW, Ware CB, et al(1999) Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nature Med 5: 101-106
91. Hampel M, Padberg F, Buch K, Unger J, Stuebner S, Moeller HJ (1999) Diagnose und Therapie der Demenz vom Alzheimer-Typ. Dtsch Med Wochenschr 124: 124-129
92. Hansen LA, Daniel SE, Wilcock GK, Love S (1998) Frontal cortical synaptophysin in Lewy body disease: relation to Alzheimer's disease and dementia. J Neurol Neurosurg Psychiatry 64: 653-656
93. Harding AJ, Halliday GM (1998) Simplified neuropathological diagnosis of dementia with Lewy bodies. Neuropathol Appl Neurobiol 24: 195-201
94. Hardy J (1997) Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 20: 154-159
95. Haroutunian V, Perl DP, Parohit DP, Narin D, Khan K, Lantz M, et al (1998) Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer's disease. Arch Neurol 55: 1185-1191
96. Harvey GT, Hughes J, McKeith IG, Briel R, Ballard C, Gholkar A, et al (1999) Magnetic resonance imaging differences between dementia with Lewy bodies and Alzheimer's disease: a pilot study. Psychol Med 29: 181-187
97. Hashimoto M, Kitagaki H, Imamura T, Hirono N, Shimomura T, Kazui H, et al (1998) Medial, temporal, and whole-brain atrophy in dementia with Lewy bodies - a volumetric MRI study. Neurology 51: 357-362
98. Hatanpää K, Isaacs KR, Shirao T, Brady DR, Rapoport SI (1999) Loss of proteins regulating synaptic plasticity in normal aging of the human brain and in Alzheimer's disease. J Neuropathol Exp Neurol 58: 637-643
99. Heffernam JM, Eastwood SL, Nagy Z, Sanders MW, McDonald B, Harrison PJ (1998) Temporal cortex synaptophysin mRNA is reduced in Alzheimer's disease and is negatively correlated with the severity of dementia. Exp Neurol 150: 235-239
100. Higgins LS (1999) Animal models of Alzheimer's disease. Molec Med Today 5: 274-276
101. Holscher C (1998) Possible causes of Alzheimer's disease - amyloid fragments, free radicals, and calcium homeostasis. Neurobiol Dis 5: 129-141
102. Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, et al (1998) Mutation-specific impairments in distinct tau isoforms of hereditary FTDP-17. Science 282: 1914-1917
103. Hulette CN, Welsh-Bohmer DA, Murray MG, et al (1998) Neuropathological and neuropsychological changes in "normal" aging; evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 57: 1168-1174
104. (1-42) and tau levels in CSF. Neurology 52: 1555-1562
105. Hux MJ, Obrien BJ, Iskedjian M, Goeree R, Gognon M, Gauthier S (1998) Relation between severity of Alzheimer's disease and costs of caring. Can Med Ass J 159: 457-465
106. Hyman BT (1998) New neuropathological criteria for Alzheimer's disease. Arch Neurol 55: 1174-1176
107. Hyman BT, Trojanowski JQ (1997) Editorial on Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 56: 1095-1097
108. Ince PG, Perry EK, Morris AM (1998) Dementia with Lewy bodies. A distinct non-Alzheimer dementia syndrome? Brain Pathol 8:299-324
109. Iraizoz I, Gutjarro JL, Gonzalo LM, de Lacalle S (1999) Neuropathological changes in the nucleus basalis correlate with clinical measures of dementia. Acta Neuropathol 98: 186-196
110. Irizarry MC, Growdon W, Gomez-Isla T, Newell K, George JM, Clayton DF, et al (1998) Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain α-synuclein immunoreactivity. J Neuropathol Exp Neurol 57: 334-337
111. Ishii K, Imamura T, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, et al (1998) Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer-disease. Neurology 51: 125-130
112. Jackson M, Lennox G, Lowe J (1996) Motor neurone disease-inclusion dementia. Neurodegeneration 5: 339-350
113. Jellinger KA (1997) Morphologic substrates of dementia in parkinsonism. A critical update. J Neural Transm [Suppl 51]: 57-82
114. Jellinger KA (1998) Alzheimer type lesions in Huntington's disease. J Neural Transm 105: 787-800
115. Jellinger K, Bancher C (1998) Senile dementia with tangles (Tangle predominant form of senile dementia). Brain Pathol 8: 367-376
116. Jellinger KA, Bancher C (1998) Neuropathology of Alzheimer's disease; a critical update. J Neural Transm [Suppl 54]: 77-95
117. Jensen M, Schroeder J, Blamberg M, Engval B, Pantel J, et al (1999) Cerebrospinal fluid Ab-42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann Neurol 45: 504-511
118. Jonker C, Schmand B, Lindeboom J, Havekes LM, Launer LJ (1998) Association between apolipoprotein E ε-4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia. Arch Neurol 55: 1065-1069
119. Jorm AF, Jolly D (1998) The incidence of dementia: A meta-analysis. Neurology 51: 728-733
120. Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K. Arai H, et al (1998) Longitudinal study of cerebrospinal fluid levels of tau, A β1-40, and A β1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 44: 17-26
121. Kanowski S (1998) Cost-benefit evaluation of drug treatment for Alzheimer's disease. Arch Gerontol Geriatr [Suppl 6]: 275-280
122. Kasa P, Rakonczay Z, Gulyai K (1997) The cholinergic system in Alzheimer's disease. Progr Neurobiol 52: 511-535
123. Kaye JA (1998) Diagnostic challenges in dementia. Neurology 51: 245-252
124. Kertesz A, Munoz DG (eds) (1999) Pick's disease and Pick's complex. Wiley-Liss, Baltimore
125. Khachaturian ZS (1985) Diagnosis of Alzheimer's disease. Arch Neurol 42: 1097-1105
126. Kienzl E, Jellinger K, Puchinger L, Crandal BM, Arendash GW (1997) Profiles of brain phospholipids and fatty acids in Alzheimer's disease brain. In: Teelken A, Korf J (eds) Neurochemistry. Cellular, molecular, and clinical aspects. Plenum Press, New York London, pp 33-38
127. Kitamura Y, Shimohama S, Kamoshima W, Ota T, Matsuoka Y, Nomura Y, Smith MA, Perry G, Whitehouse PJ, Taniguchi T (1998) Alteration of proteins regulating apoptosis. Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease. Brain Res 780: 260-269
128. Klunk WE, Panchalingam K, McClure RJ, Stanlay JA, Pettegrew JW (1998) Metabolic alterations in postmortem Alzheimer's disease brain are exaggerated by Apo-E4. Neurobiol Aging 19: 511-515
129. Knopman DS, Berg JD, Thomas R, Grundman M, Thal LJ, et al (1999) Nursing home placement is related to dementia progression. Neurology 52: 714-718
130. Kovacs DM, Tanzi RE (1998) Monogenic determinants of familial Alzheimer's disease - presenilin-1 mutations (Review). Cell Molec Life Sci 54: 902-909
131. Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficaro EP. Foster NL, et al (1999) In vivo mapping of cerebral acetyl cholinesterase activity in aging and Alzheimer's disease. Neurology 52: 691-699
132. Lassman H, Bancher C, Breitschof H, Wegiel J, Bobinski M, Jellinger K, Wisniewski HM (1995) Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol 89: 35-41
133. Launer LJ, Andersen K, Dewey ME, Letenneur L, Ott A, Amaducci LA, et al (1999) Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. Neurology 52: 78-84
134. Lautenschlager N, Kurz A, Müller U (1999) Erbliche Ursache und Risikofaktoren der Alzheimer-Krankheit. Nervenarzt 70: 195-205
135. Lautenschlager NT, Bickeböller H, Reischies M, Gessner R, Bertram L, et al (1999) The risk for Alzheimer's disease conferred by apolipoprotein genotype is age dependent. Neurology 52 [Suppl 2]: A 322
136. Lehmann DJ, Johnston C, Smith AD (1997) Synergy between the genes for butyrylcholin-esterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum Mol Genet 6: 1933-1936
137. Lendon CL, Lynch T, Norton J, McKeel DW, Busfield F, et al (1998) Hereditary dysphonic inhibition dementia: a frontotemporal dementia linked to 17q21-22. Neurology 50: 1546-1555
138. Lippa CF, O'Connel B, Smith TW et al. (1998) Dementia with Lewy bodies: influence of ApoE genotype on Aβ-40 and Aβ-42 deposition. J Neuropathol Exp Neurol 57:515 (abstr.)
139. Lippa CF, Smith TW, Perry E (1999) Dementia with Lewy bodies: choline acetytransferase parallels nucleus basalis pathology. J Neuronal Transm 106: 525-536
140. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Report of the NINDS-SPSP International Workshop. Neurology 47: 1-9
141. Litvan I, Agid Y, Goetz C, Jankovic J, Wenning G, Brandel JP, et al (1997) Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathological study. Neurology 48: 119-125
142. Litvan I, Agid Y, Jankovic J, Goetz C, Brandel JP, Lai EC, et al (1996) Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology 46: 922-930
143. Litvan I, Campbell G, Mangone CA, Verny M, McKee A, Chaudhuri KR, et al (1997) Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study. Brain 120: 65-74
144. Litvan I, Grimes DA, Lang AE, Jankovic J, McKee A, Verny M, et al (1999) Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration. J Neurol (in press)
145. Litvan I, Paulsen JS, Moega MS, Ciranings JL (1998) Neuropsychiatric assessment of patients with hyperkinetic and hypokinetic movement disorders. Arch Neurol 55: 1313-1319
146. Luukinen H, Viramo P, Koski K, Laippala P, Kivela SL (1999) Head injuries and cognitive decline among older adults: a population-based study. Neurology 52: 557-562
147. Mandelkow EM, Mandelkow E (1998) Tau in Alzheimer's disease. Trends Cell Biol 8: 425-427
148. Mann DMA (1998) Dementia of frontal type and dementias with subcortical gliosis. Brain Pathol 8: 325-338
149. Mann DMA, Brown SMP, Owen F, Baba M, Iwatsubo T (1998) Amyloid β-protein (A-β) deposition in dementia with Lewy bodies - predominance of A-β (42) and paucity of A-β (40) compared with sporadic Alzheimers-disease. Neuropathol Appl Neurobiol 42: 187-194
150. Markesberry WR (ed) (1998) Neuropathology of dementing disorders. E. Arnold, London
151. Markesberry WR, Carney JM (1999) Oxidative alterations in Alzheimer's disease (Review). Brain Pathol 9: 133-146
152. Martinez M, Campion C, Brice A, Hannequin D, Dubois B, Didierjean O, et al (1998) Apolipoprotein E ε4 allele and familial aggregation of Alzheimer disease. Arch Neurol 55: 810-816
153. Masliah E (1998) Mechanisms of synaptic pathology in Alzheimer's disease. J Neural Transm [Suppl 53]: 147-158
154. Masliah E, Mallory M, Alford M, Tanaka S, Hansen LA (1998) Caspase dependent DNA fragmentation might be associated with excitotoxicity in Alzheimer disease. J Neuropathol Exp Neurol 57: 1041-1052
155. Manila PM, Röyttä M, Torikka H, et al (1998) Cortical Lewy bodies and Alzheimer type changes in patients with Parkinson's disease. Acta Neuropathol 95: 576-582
156. Mayeux R, Saunders AM, Shea S, et al (1998) Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. N Engl J Med 338: 506-511
157. Mayeux R, Costa R, Bell K, Merchant C, Tang MX, Jacobs D (1999) Reduced risk of Alzheimer's disease among individuals with low caloric intake. Neurology 52: A296-297
158. McGeer EG, McGear PL (1998) Mini-review - The importance of inflammatory mechanisms in Alzheimer-disease. Exp Gerontol 33: 371-378
159. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 47: 1113-1124
160. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34: 939-944
161. McNamara MJ, Gomezisla T, Hyman BT (1998) Apolipoprotein E genotype and deposits of a-β-40 and a-β-42 in Alzheimer-disease. Arch Neurol 55:1001-1004
162. Merchant C, Tang MX, Albert S, et al (1999) The influence of smoking on the risk of Alzheimer's disease. Neurology 52: 1405-1412
163. Mielke R, Kessler J, Szelies B, Herzolz K, Wieshard K, Heiss WD (1998) Normal and pathological aging - findings of positron emission tomography. J Neural Transm 105: 821-837
164. Mirra SS, Hart MN, Terry RD (1993) Making the diagnosis of Alzheimer's disease. A primer for practicing pathologists. Arch Pathol Lab Med 117: 132-144
165. Mirra SS, Murrell JR, Gearing M, et al (1999) Tau pathology in a familiy with dementia and P301L mutation in tau. J Neuropathol Exp Neurol 58: 335-345
166. Monza D, Soliveri P, Radice D, Frioni V, Testa D, et al (1998) Cognitive dysfunction and impaired organization of complex motility in degenerative parkinsonian syndrome. Arch Neurol 55: 372-378
167. Morris CM, Massey HM, Benjamin R, Leake A, Broadbent C, Griffiths M, et al (1996) Molecular biology of APO E alleles in Alzheimer and non-Alzheimer dementias. J Neural Transm [Suppl 47]: 205-218
168. Morrison JH, Hof PR (1997) Life and death of neurons in the aging brain. Science 278: 412-419
169. Mouton PR, Mortin LJ, Calhoun ME, Dal Forno G, Price DL (1998) Cognitive decline strongly correlates with cortical atrophy in Alzheimer's disease. Neurobiol Aging 19: 371-377
170. Muench G, Schinzel R, Loske C, Wong A, Durany N, Li JJ, et al (1998) Alzheimer's disease - synergistic effects of glucose deficit, oxidative stress and advanced glycation end products. J Neural Transm 105: 439-461
171. Muenter MD, Forno LS, Hornykiewicz O, Kish SJ, Maraganore DM, Caselli RJ, et al (1998) Hereditary form of parkinsonism-dementia. Ann Neurol 43: 768-781
172. Mulhaup G, Masters CL, Beyreuter K (1998) Oxidative stress in Alzheimer's disease. Alzheimer Rep 1: 147-154
173. Myers RH, Schaefer EJ, Wilson PWF, et al (1996) Apolipoprotein E ε4 association with dementia in a population-based study. The Framingham study. Neurology 46: 673-677
174. Nagy Z, Esiri MM, Hindlay NJ, Joachim C, Morris JH, King EMF, et al (1998) Accuracy of clinical operational diagnostic criteria for Alzheimer's disease an relation to different pathological diagnostic protocols. Dementia Geriat Cogn Disord 9: 219-226
175. Nasreddine ZS, Loginov M, Clark LN, et al (1999) From genotype to phenotype: a clinical, pathological, and biochemical investigation of frontotemporal demen tia and parkinsonism (FTDP-17) caused by the P301L tau mutation. Ann Neurol 45: 704-715
176. National Institute on Aging/Alzheimer's Association Working Group (1996) Apolipoprotein E genotyping in Alzheimer's disease. Lancet 347: 1091-1095
177. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al (1998) Frontotemporal lobar degeneration. A consensus on clinical diagnostics criteria. Neurology 51: 1546-1554
178. Nemetz PN, Leibson C, Naessens JM, Beard M, Kokmen E, Annegers JF, Kurland LT (1999) Traumatic brain injury and time to onset of Alzheimer's disease: a population-based study. Am J Epidemiol 149: 32-40
179. Oliva R, Tolosa E, Ezquerra M, Molinuovo JL, Valldeoriola F, et al (1998) Significant changes in the tau A0 and A3 alleles in progressive supranuclear palsy and improved genotyping by silver detection. Arch Neurol 55: 1122-1124
180. Olichney JM, Galasko D, Salmon DP, Hofstetter CR, Katzman R, Thal J (1998) Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. Neurology 51: 351-357
181. O'Meara ES, Kukull WA, Sheppard L, et al (1997) Head injury and risk of Alzheimer's disease by apolipoprotein E genotype. Am J Epidemiol 146:373-384
182. Ott A, Breteler MMB, Vanharskamp F, Stijnen T, Hotman A (1998) Incidence and risk of dementia - the Rotterdam study. Am J Epidemiol 147: 574-580
183. Ott A, Slooter AJC, Hofman A, Vanharskamp F, Witteman JCM, Vanbroeckhoven C, et al (1998) Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study - The Rotterdam study. Lancet 351: 1840-1843
184. Pahwa R, Paolo A, Troester A, Koller W (1998) Cognitive inpairment in Parkinson's disease. Eur J Neurol 5: 431-443
185. Panegyres PK, Mamotte CDS, Vasikaran SD, et al (1999) Butyrylcholinesterase K variant and Alzheimer's disease. J Neurol 246: 369-370
186. Pappolla MA, Chyan YJ, Qrer RA. Hsiao K, Perry G, Smith MA, et al (1998) Evidence of oxidative stress and in vivo neurotoxicity of β-amyloid in a transgenic mouse model of Alzheimer's disease. Am J Pathol 152: 871-877
187. Pasquier F (1999) Early diagnosis of dementia: neuropsychology. J Neurol 246: 6-15
188. Pasquier P, Delacourte A (1998) Non-Alzheimer degenerative dementias. Curr Opin Neurol 11: 417-427
189. Patterson CJS, Gauthier S, Bergman H, Cohen CA, Feighner JW, Feldman H, Hogan DB (1999) The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia (Review). Can Med Ass J 160 [Suppl 21: S1-S15
190. Perry E, Walker M, Grace J, Perry R (1999) Acetylcholine in mind: a neurotransmitter correlate of consciousness? (Review). Trends Neurosci 22: 273-280
191. Perry R, McKeith I, Perry E (1998) Dementia with Lewy bodies: the second most common cause of dementia? Neurosci News 1: 28-36
192. Petersen RB, Tabaton M, Monari L, Richardson SL, Lynches T, Manetto V, et al (1995) Familial progressive subcortical gliosis: presence of prions and linkage to chromosome 17. Neurology 45: 1062-1067
193. Petit D, Montplaisir J, Riekkinen P, Soininen H, Riekkinen P Jr (1999) Electrophysiological tests. In: Gauthier S (ed) Clinical diagnosis and management of Alzheimer's disease, 2nd edn. M. Dunitz Ltd, London, pp 133-154
194. Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, et al (1998) Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol 43: 815-825
195. Premkumar S, Song Y, Perocak-Vance MA, Haines JL, Rogaeva E, Scott WK, et al (1998) Analysis of the association between bleomycin hydrolase and Alzheimer disease in Caucasians. Neurobiol Aging 19: S68
196. Price H, Morris JC (1999) Tangles and plaques in non-demented aging and "preclinical" Alzheimer's disease. Ann Neurol 45: 358-368
197. Reed LA, Schmidt ML, Wszolet ZK, Bacin BJ, et al (1998) The neuropathology of a chromosome 17-linked autosomal dominant parkinsonism and dementia ("pallido-ponto-nigral degeneration"). J Neuropathol Exp Neurol 57: 588-601
198. Reisberg B, Frarissen EH, Souren LEN, Auer S, Kanowsky S (1998) Progression of Alzheimer's disease; variability and consistency. J Neural Transm [Suppl 54]: 9-29
199. Reischies FM, Geiselmann B, Geßner R, Kanowski S, Wagner M, Wernicke F, et al (1997) Demenz bei Hochbetagten. Ergebnisse der Berliner Altersstudie. Nervenarzt 68: 719-729
200. Renbaum P, Levylahad E (1998) Monogenic determinants of familial Alzheimer's disease - presenilin-2 mutations. Cell Molec Life Sci 54: 910-919
201. Rizzu P, Van Swieten JC, Joosse M, Hasegawa M, Stevens M, Tibben A, et al (1999) High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. Am J Hum Genet 64: 414-421
202. Rocca WA. Cha RH, Waring SC, Kokmen E (1998) Incidence of dementia and Alzheimer's disease - a reanalysis of data from Rochester. Minnesota, 1975-1984. Am J Epidemiol 148: 51-62
203. Rojo A, Pernaute RS, Fontan A, Ruiz PG, Honnorat J, et al (1999) Clinical genetics of familial progressive supranuclear palsy. Brain 122: 1233-1245
204. Rubinsztein DC, Easten DP (1999) Apolipoprotein E genetic variation and Alzheimer's disease; a meta-analysis. Dement Geriatr Cogn Disord 10: 199-209
205. Saleh A, Dubelaar EJG, Mulder M, Swaab DF (1998) Aggravated decrease in the activity of nucleus basalis neurons in Alzheimer disease is apolipoprotein E-type dependent. Proc Natl Acad Sci USA 95: 11445-11449
206. Samuel W, Alford M, Hofstetter CR, Hansen L (1997) Dementia with Lewy bodies versus pure Alzheimer's disease: differences in cognition, neuropathology, cholinergic dysfunction, and synaptic density. J Neuropathol Exp Neurol 56: 499-508
207. Samuels SC, Silverman JM, Marin DB, Peskind ER, et al (1999) CSF β-amyloid, cognition, and APOE genotype in Alzheimer's disease. Neurology 52: 547-551
208. Schellenberg GD (1999) Genetic studies on progressive supranuclear palsy. In: Litvan I (ed) First Int. Brain-storming Conference on PSP, Bethesda, MD, pp 21-31
209. Scheltens P (1999) Early diagnosis of dementia: neuroimaging. J Neurol 246: 16-20
210. Schnider A (1999) Degenerative und symptomatische Demenzen. In: Hopf H, Deuschl G, Diener HC, Reichmann H (Hrsg) Neurologie in Praxis und Klinik, Bd.1, 3. Aufl. G.Thieme, Stuttgart New York, S 106-129
211. Seabrook GR, Rosahl TW (1999) Transgenic animals relevant to Alzheimer's disease. Neuropharmacology 38: 1-17
212. Selkoe DJ (1998) The cell biology of b-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol 8: 447-453
213. Selkoe DJ (1999) Translating cell biology into therapeutic advances in Alzheimer's disease (Review). Nature 399 [Suppl 5]: A23-A31
214. Seno H, Ishino H, Inagaki T, Lijima M, Kaku K, Inata T (1999) A neuropathological study of dementia in nursing homes over a 17-year period, in Shimane Prefecture, Japan. Gerontology 45: 44-48
215. Sergeant N, Wattez A, Delacourte A (1999) Neurofibrillary degeneration in progressive supranucelar palsy and corticobasal degeneration: tau pathologies with exclusively "exon 10" isoforms. J Neurochem 72: 1243-1249
216. Seshadri S, Woff PA, Beiser A, Au R, Mcnulty K, White R, et al (1997) Lifetime risk of dementia and Alzheimer's disease - the impact of mortality on risk estimates in the Framingham study. Neurology, 49: 1498-1504
217. Sheng W, Zhou XM, Mrak RE, Griffin WST (1998) Progressive neuronal injury with amyloid plaque formation in Alzheimer's disease. J Neuropathol Exp Neurol 57: 714-717
218. Shimomura T, Mori E, Yamashita H, Imamura T, Hirono N, Hashimoto M, et al (1998) Cognitive loss in dementia with Lewy bodies and Alzheimer's disease. Arch Neurol 55: 1547-1552
219. Shoffner JM (1997) Oxidative phosphorylation defects and Alzheimer's disease. Neurogenetics 1: 13-19
220. Sjoegren M, Minthon L, Passant U, Blennow K, Wallin A (1998) Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease. Neurobiol Aging 19: 379-384
221. Slooter AJC, Cruts M, Kalmijn S, Hofman A, Breteler MMB, Van Broeckhoven C, et al (1998) Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam study. Arch Neurol 55: 964-968
222. Smith GE, Bohac DL, Waring SC, Kokmen E, Tangalos EG, Ivnik RJ, et al (1998) Apolipoprotein E genotype influences cognitive phenotype in patients with Alzheimer's disease but not in healthy control subjects. Neurology 50: 355-362
223. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PLR, Siedlak SL, et al (1998) Amyloid-β deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 70: 2212-2215
224. Sparks DL, Scheff SW, Liu H, Landers T, Danner F, Coyne CM, et al (1996) Increased density of senile plaques (SP), but not neurofibrillary tangles (NFT), in non-demented individuals with the apolipoprotein E4 allele: comparison to confirmed Alzheimer's disease patients. J Neurol Sci 138: 97-104
225. Spillantini MG, Bird TD, Ghetti B (1998) Frontotemporal dementia and Parkinsonism linked to chromosome 17: a new group of tauopathies. Brain Pathol 8: 387-402
226. Spillantini MG, Goedert M (1998) Tau protein pathology in neurodegenerative diseases. TINS 21: 428-433
227. Sramek JJ: Cutler NR (1999) Recent development in the drug treatment of Alzheimer's disease (Review). Drugs Aging 14: 359-373
228. Stadelmann C, Brück W, Bancher C, Jellinger K, Lassmann H (1998) Alzheimer disease: DNA fragmentation indicates increased neuronal vulnerability, but not apoptosis. J Neuropathol Exp Neurol 57: 456-464
229. Stadelmann C, Deckwerth TL, Scrinivasan A, Bancher C, Brück W, Jellinger K, Lassmann H (1999) Activation of caspase-3 in single apopototic neurons and granules of granulovacuolar degeneration in Alzheimer disease and Down's syndrome: a role for autophagy as antiapoptotic counterregulatory mechanism? Am J Pathol (in press)
230. Storey E, Cappal R (1999) The amyloid precursor protein of Alzheimer's disease and the A beta peptide (Review). Neuropathol Appl Neurobiol 25: 81-97
231. Tanzi RE, Kovacs DM, Kim T-W, Moir RD, Guenette SY, Wasco W (1996) The gene defects responsible for familial Alzheimer's disease. Neurobiol Dis 3: 159-168
232. Thal DR, Arendt T, Waldmann G, Holzer M, Zedlick D, Rub U, et al (1998) Progression of neurofibrillary changes and PHF-tau in end stage Alzheimer's disease is different from plaque and neuroglial pathology. Neurobiol Aging 19: 517-525
233. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group (1998) Consensus report of the Working Group on "Molecular and biochemical markers of Alzheimer disease". Neurobiol Aging 19: 109-116
234. Thomassen R, van Schaick HW, Blansjaar BA (1998) Prevalence of dementia over age 100. Neurology 50: 283-286
235. Tilley L, Morgan K, Kalsheker N (1998) Genetic risk factors in Alzheimer's disease (Review). J Clin Pathol -Clin Molec Pathol Edition 51: 293-304
236. Tolnay M, Probst A, Monsch AU, Steahelin HB, Egensperger R (1998) Apolipoprotein E allele frequencies in argyrophilic grain disease. Acta Neuropathol 96: 225-527
237. Tolnay M, Monsch AU, Staehelin HB, Probst A (1999) Die Silberkornkrankheit - Abgrenzung zur Alzheimer'schen Erkrankung. Pathologe 20: 159-168
238. Van Duijn CM, Clayton D, Chandra V, Fratiglioni L, Graves AB, Heyman A, et al (1991) Familial aggregation of Alzheimer's disease and related disorders: a collaborative re-analysis of case-control studies, Int J Epidemiol 20: 13-20
239. Varma AR, Snowden JS, Lloyd JJ, Talbot PR, Mann DMA, Neary D (1999) Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry 66: 184-188
240. Visser PJ, Scheltens P, Verhey FRJ, Schmand P, Launer LJ, et al (1999) Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. J Neurol 246: 477-485
241. Wakabayashi K, Kakita A, Hayashi S, et al (1998) Apolipoprotein E ε4 allele and progression of cortical Lewy body pathology in Parkinson's disease. Acta Neuropathol 95: 450-454
242. Waring SC, Rocca WA, Petersen RC, O'Brien PC, Tantalos EG, Kokmen E (1999) Postmenopausal estrogen replacement therapy and risk of AD. A population based study. Neurology 52: 965-970
243. Weiner MF, Vega G, Risser RC, Honig LB, Cullum CM, Brumpacker D, et al (1999) Apolipoprotein Eε4. other risk factors, and course of Alzheimer's disease. Biol Psychiatry 45: 633-638
244. Weltgesundheitsorganisation (1993) In: Dilling H, Mombour W, Schmidt MH (Hrsg) Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel V (F). Huber, Bern
245. Wolf H, Gruenwald M, Ecker GM, Zedlick D, Bettin S, Dannenberg C, et al (1998) The prognosis of mild cognitive impairment in the elderly. J Neural Transm [Suppl 54]: 31-50
246. Whitehouse PJ (1999) Cholinesterase inhibitors in Alzheimer's disease: are they worth the cost? CNS Drugs 11: 167-147
247. Yamatsuji T, Matsui T, Okamoto T, et al (1996) G-protein-mediated neuronal DNA fragmentation induced by familial Alzheimer's disease-associated mutants of APP. Science 272: 1349-1352
248. Yasuda M, Mori E, Kitagaki H, Yamashita H, Hirono N, Shimada K, et al (1998) Apolipoprotein E ε-4 allele and whole brain atrophy in late-onset Alzheimer's disease. Am J Psychiatry 155: 779-784
249. Zachhuber C, Leblhuber F, Bancher C, Jellinger K, Drlicek M (1999) Frontallappen-Demenzen. Klinisch-pathologische Fallberichte. Fortschr Neurol Psychiat 67: 68-74
250. Zhang ZJ, Lappi DA, Wrenn CC, Milner TA, Wiley RG (1998) Selective lesion of the cholinergic basal forebrain causes a loss of cortical neuropetide Y and somatostatin neurons. Brain Res 800: 198-206
251. Zhou L, Miller BL, McDaniel CH, Kelly L, Kim OJ, Miller CA (1998) Frontotemporal dementia: neuropil spheroids and presynaptic terminal degeneration. Ann Neurol 44: 99-109
252. Zubenko GS, Hughes HB, Stiffler JS (1999) Neurobiological correlates of a putative risk allele fo Alzheimer's disease on chromosome 12q. Neurology 52: 725-732